Published in Proc Natl Acad Sci U S A on April 15, 2013
Crosstalk between mitogen-activated protein kinases and mitochondria in cardiac diseases: therapeutic perspectives. Pharmacol Ther (2014) 0.88
Lactosylceramide promotes hypertrophy through ROS generation and activation of ERK1/2 in cardiomyocytes. Glycobiology (2014) 0.85
Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol (2015) 0.81
Regulatory roles of conserved phosphorylation sites in the activation T-loop of the MAP kinase ERK1. Mol Biol Cell (2016) 0.80
Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy. Front Pharmacol (2015) 0.80
Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation. Mol Biol Cell (2015) 0.79
Diet and sex modify exercise and cardiac adaptation in the mouse. Am J Physiol Heart Circ Physiol (2014) 0.78
Heart failure-specific changes in protein kinase signalling. Pflugers Arch (2014) 0.78
Selumetinib, an Oral Anti-Neoplastic Drug, May Attenuate Cardiac Hypertrophy via Targeting the ERK Pathway. PLoS One (2016) 0.77
Scaffold Proteins Regulating Extracellular Regulated Kinase Function in Cardiac Hypertrophy and Disease. Front Pharmacol (2016) 0.77
Phosphorylation or Mutation of the ERK2 Activation Loop Alters Oligonucleotide Binding. Biochemistry (2016) 0.76
From Bench to Bedside: New Approaches to Therapeutic Discovery for Heart Failure. Heart Lung Circ (2016) 0.76
G protein βγ subunits regulate cardiomyocyte hypertrophy through a perinuclear Golgi phosphatidylinositol 4-phosphate hydrolysis pathway. Mol Biol Cell (2015) 0.76
Sodium Ferulate Protects against Angiotensin II-Induced Cardiac Hypertrophy in Mice by Regulating the MAPK/ERK and JNK Pathways. Biomed Res Int (2017) 0.75
The Heparan Sulfate Proteoglycan Glypican-6 Is Upregulated in the Failing Heart, and Regulates Cardiomyocyte Growth through ERK1/2 Signaling. PLoS One (2016) 0.75
Na+/H+ exchanger isoform 1 induced cardiomyocyte hypertrophy involves activation of p90 ribosomal s6 kinase. PLoS One (2015) 0.75
The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy. Int J Mol Sci (2016) 0.75
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem (1995) 14.14
Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol (2006) 10.71
Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med (2000) 4.13
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J (2000) 4.09
Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell (1998) 3.80
Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet (2007) 3.47
Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation (2004) 3.16
Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation (2002) 3.15
Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther (2010) 2.65
Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ Res (2002) 2.59
Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol (2011) 2.54
STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol (2004) 2.53
Cell death assays for drug discovery. Nat Rev Drug Discov (2011) 2.51
The stability of the G protein-coupled receptor-beta-arrestin interaction determines the mechanism and functional consequence of ERK activation. J Biol Chem (2002) 2.47
Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. J Clin Invest (1997) 2.44
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature (2003) 2.38
An FHL1-containing complex within the cardiomyocyte sarcomere mediates hypertrophic biomechanical stress responses in mice. J Clin Invest (2008) 2.19
The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death. Circulation (2006) 2.13
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med (2005) 2.02
Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol (2008) 1.95
MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) (2008) 1.95
Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo. Proc Natl Acad Sci U S A (2007) 1.93
Decompensation of cardiac hypertrophy: cellular mechanisms and novel therapeutic targets. Physiology (Bethesda) (2007) 1.78
Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res (2009) 1.71
MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation (2004) 1.69
Differential nucleocytoplasmic shuttling of beta-arrestins. Characterization of a leucine-rich nuclear export signal in beta-arrestin2. J Biol Chem (2002) 1.66
Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload. Circulation (2004) 1.59
Depletion of mitogen-activated protein kinase using an antisense oligodeoxynucleotide approach downregulates the phenylephrine-induced hypertrophic response in rat cardiac myocytes. Circ Res (1996) 1.57
A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med (2008) 1.56
Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol (2009) 1.39
Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy. Ann N Y Acad Sci (2010) 1.23
Serine 105 phosphorylation of transcription factor GATA4 is necessary for stress-induced cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A (2011) 1.23
CIB1 is a regulator of pathological cardiac hypertrophy. Nat Med (2010) 1.20
Cardiac myocyte gene expression profiling during H2O2-induced apoptosis. Physiol Genomics (2006) 1.12
Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol (2005) 1.05
Cardiac hypertrophy: a risk factor for QT-prolongation and cardiac sudden death. Toxicol Pathol (2006) 1.04
Sustained activation of p42/p44 mitogen-activated protein kinase during recovery from simulated ischaemia mediates adaptive cytoprotection in cardiomyocytes. Biochem J (2000) 0.99
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Inhibition of phenylephrine-induced cardiomyocyte hypertrophy by activation of multiple adenosine receptor subtypes. J Pharmacol Exp Ther (2004) 0.93
β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway. Cardiovasc Res (2012) 0.92
Enhanced binding of calmodulin to the ryanodine receptor corrects contractile dysfunction in failing hearts. Cardiovasc Res (2012) 0.85
Novel single chain cAMP sensors for receptor-induced signal propagation. J Biol Chem (2004) 5.00
A FlAsH-based FRET approach to determine G protein-coupled receptor activation in living cells. Nat Methods (2005) 3.11
Beta2-adrenergic receptor redistribution in heart failure changes cAMP compartmentation. Science (2010) 2.99
Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation (2009) 2.88
Measurement of the millisecond activation switch of G protein-coupled receptors in living cells. Nat Biotechnol (2003) 2.84
Widespread receptivity to neuropeptide PDF throughout the neuronal circadian clock network of Drosophila revealed by real-time cyclic AMP imaging. Neuron (2008) 2.73
Cyclic AMP imaging in adult cardiac myocytes reveals far-reaching beta1-adrenergic but locally confined beta2-adrenergic receptor-mediated signaling. Circ Res (2006) 2.66
International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev (2007) 2.62
Persistent cAMP-signals triggered by internalized G-protein-coupled receptors. PLoS Biol (2009) 2.59
Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ Res (2004) 2.58
Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol (2011) 2.54
Gi protein activation in intact cells involves subunit rearrangement rather than dissociation. Proc Natl Acad Sci U S A (2003) 2.52
Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol (2008) 2.51
Building a new conceptual framework for receptor heteromers. Nat Chem Biol (2009) 2.41
Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature (2003) 2.38
Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation (2002) 2.10
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation (2009) 2.07
Dynamics of receptor/G protein coupling in living cells. EMBO J (2005) 2.06
Analysis of receptor oligomerization by FRAP microscopy. Nat Methods (2009) 2.06
The transcriptional repressor Nab1 is a specific regulator of pathological cardiac hypertrophy. Nat Med (2005) 2.02
Fluorescent sensors for rapid monitoring of intracellular cGMP. Nat Methods (2006) 1.96
Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. N Engl J Med (2014) 1.89
Determination of onset of sexual maturation and mating behavior by melanocortin receptor 4 polymorphisms. Curr Biol (2010) 1.82
G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82
Single-molecule analysis of fluorescently labeled G-protein-coupled receptors reveals complexes with distinct dynamics and organization. Proc Natl Acad Sci U S A (2012) 1.82
Interplay of Ca2+ and cAMP signaling in the insulin-secreting MIN6 beta-cell line. J Biol Chem (2005) 1.80
Inhibition of Na(+)-H(+) exchange prevents hypertrophy, fibrosis, and heart failure in beta(1)-adrenergic receptor transgenic mice. Circ Res (2002) 1.79
Gentamicin-collagen sponge reduces sternal wound complications after heart surgery: a controlled, prospectively randomized, double-blind study. J Thorac Cardiovasc Surg (2011) 1.78
Direct evidence for a beta 1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest (2004) 1.77
Sweet taste receptor expressed in pancreatic beta-cells activates the calcium and cyclic AMP signaling systems and stimulates insulin secretion. PLoS One (2009) 1.71
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol (2006) 1.71
Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci (2010) 1.70
Turn-on switch in parathyroid hormone receptor by a two-step parathyroid hormone binding mechanism. Proc Natl Acad Sci U S A (2005) 1.63
Molecular basis of inverse agonism in a G protein-coupled receptor. Nat Chem Biol (2005) 1.60
A new type of ERK1/2 autophosphorylation causes cardiac hypertrophy. Nat Med (2008) 1.56
G Protein activation without subunit dissociation depends on a G{alpha}(i)-specific region. J Biol Chem (2005) 1.55
Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging (2013) 1.54
Echocardiographic evaluation of systolic and diastolic function in patients with cardiac amyloidosis. Am J Cardiol (2011) 1.53
Gs activation is time-limiting in initiating receptor-mediated signaling. J Biol Chem (2006) 1.52
Beta-arrestin binding to the beta2-adrenergic receptor requires both receptor phosphorylation and receptor activation. J Biol Chem (2005) 1.50
Echocardiographic quantification of regional deformation helps to distinguish isolated left ventricular non-compaction from dilated cardiomyopathy. Eur J Heart Fail (2012) 1.45
FRET measurements of intracellular cAMP concentrations and cAMP analog permeability in intact cells. Nat Protoc (2011) 1.45
Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest (2007) 1.44
Tei index in fabry disease. J Am Soc Echocardiogr (2011) 1.44
Cardiac hypertrophy: targeting Raf/MEK/ERK1/2-signaling. Int J Biochem Cell Biol (2009) 1.39
Internalization determinants of the parathyroid hormone receptor differentially regulate beta-arrestin/receptor association. J Biol Chem (2001) 1.37
Altered calcium handling is critically involved in the cardiotoxic effects of chronic beta-adrenergic stimulation. Circulation (2004) 1.36
Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. Mol Endocrinol (2003) 1.33
Monocytes/macrophages prevent healing defects and left ventricular thrombus formation after myocardial infarction. FASEB J (2012) 1.31
Real-time monitoring of the PDE2 activity of live cells: hormone-stimulated cAMP hydrolysis is faster than hormone-stimulated cAMP synthesis. J Biol Chem (2004) 1.30
Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function. Proc Natl Acad Sci U S A (2006) 1.29
Fluorescent labeling of tetracysteine-tagged proteins in intact cells. Nat Protoc (2010) 1.28
Autograft reinforcement to preserve autograft function after the ross procedure: a report from the german-dutch ross registry. Circulation (2009) 1.23
Monitoring of cAMP synthesis and degradation in living cells. Physiology (Bethesda) (2006) 1.20
Differential signaling of the endogenous agonists at the beta2-adrenergic receptor. J Biol Chem (2010) 1.20
Prolonged heparin-free extracorporeal membrane oxygenation in multiple injured acute respiratory distress syndrome patients with traumatic brain injury. J Trauma Acute Care Surg (2012) 1.19
Persistent cAMP signaling by internalized TSH receptors occurs in thyroid but not in HEK293 cells. FASEB J (2012) 1.17
GPCR and G proteins: drug efficacy and activation in live cells. Mol Endocrinol (2009) 1.16
Ca2+ cycling and new therapeutic approaches for heart failure. Circulation (2010) 1.16
FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke (2013) 1.15
Agonist-selective, receptor-specific interaction of human P2Y receptors with beta-arrestin-1 and -2. J Biol Chem (2008) 1.14
Molecular basis of partial agonism at the neurotransmitter alpha2A-adrenergic receptor and Gi-protein heterotrimer. J Biol Chem (2006) 1.14
A role for caspase-1 in heart failure. Circ Res (2007) 1.13
Progression of left ventricular functional abnormalities in hypertensive patients with heart failure: an ultrasonic two-dimensional speckle tracking study. J Am Soc Echocardiogr (2008) 1.11
Common genomic response in different mouse models of beta-adrenergic-induced cardiomyopathy. Circulation (2003) 1.10
GPCR-OKB: the G Protein Coupled Receptor Oligomer Knowledge Base. Bioinformatics (2010) 1.09
Dual role of the beta2-adrenergic receptor C terminus for the binding of beta-arrestin and receptor internalization. J Biol Chem (2008) 1.09
SUMO-1 controls the protein stability and the biological function of phosducin. J Biol Chem (2006) 1.08
Clinical implication of mitral annular plane systolic excursion for patients with cardiovascular disease. Eur Heart J Cardiovasc Imaging (2012) 1.08
Factors associated with the development of aortic valve regurgitation over time after two different techniques of valve-sparing aortic root surgery. J Thorac Cardiovasc Surg (2008) 1.07
A novel fluorescence method for the rapid detection of functional beta1-adrenergic receptor autoantibodies in heart failure. J Am Coll Cardiol (2007) 1.07
Cytoplasmic cAMP concentrations in intact cardiac myocytes. Am J Physiol Cell Physiol (2008) 1.07
Distinct pools of cAMP centre on different isoforms of adenylyl cyclase in pituitary-derived GH3B6 cells. J Cell Sci (2010) 1.06
Dual regulation of the parathyroid hormone (PTH)/PTH-related peptide receptor signaling by protein kinase C and beta-arrestins. Endocrinology (2002) 1.06
Regulation of the inward rectifying properties of G-protein-activated inwardly rectifying K+ (GIRK) channels by Gbeta gamma subunits. J Biol Chem (2002) 1.05
Requirements and ontology for a G protein-coupled receptor oligomerization knowledge base. BMC Bioinformatics (2007) 1.04
Investigating cardiac function using motion and deformation analysis in the setting of coronary artery disease. Circulation (2007) 1.04
Simultaneous optical measurements of cytosolic Ca2+ and cAMP in single cells. Sci STKE (2006) 1.04
Disruption of cardiac Ena-VASP protein localization in intercalated disks causes dilated cardiomyopathy. Am J Physiol Heart Circ Physiol (2003) 1.04
Iatrogenic perforation of the left heart during placement of a chest drain. Diagn Interv Radiol (2010) 1.04
Phosducin-like protein regulates G-protein betagamma folding by interaction with tailless complex polypeptide-1alpha: dephosphorylation or splicing of PhLP turns the switch toward regulation of Gbetagamma folding. J Biol Chem (2005) 1.04
Stimulating autoantibodies directed against the cardiac beta1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J (2006) 1.04
FRET-based sensors for the human M1-, M3-, and M5-acetylcholine receptors. Bioorg Med Chem (2010) 1.03
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet (2014) 1.03
Magnesium and the parathyroid. Curr Opin Nephrol Hypertens (2002) 1.03
cAMP microdomains and L-type Ca2+ channel regulation in guinea-pig ventricular myocytes. J Physiol (2007) 1.02
beta(1)-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy. Trends Cardiovasc Med (2006) 1.01
Sequential inter- and intrasubunit rearrangements during activation of dimeric metabotropic glutamate receptor 1. Sci Signal (2012) 1.01
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging (2011) 1.00